Contrasting SCYNEXIS (NASDAQ:SCYX) and Scienture (NASDAQ:SCNX)

SCYNEXIS (NASDAQ:SCYX) and Scienture (NASDAQ:SCNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares SCYNEXIS and Scienture”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60 million	1.56	-$8.61 million	($0.48)	-1.50
Scienture	$430,000.00	37.98	-$41.51 million	($2.51)	-0.16

SCYNEXIS has higher revenue and earnings than Scienture. SCYNEXIS is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for SCYNEXIS and Scienture, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1	0	1	0	2.00
Scienture	1	0	1	0	2.00

SCYNEXIS presently has a consensus target price of $3.00, suggesting a potential upside of 316.67%. Scienture has a consensus target price of $1.50, suggesting a potential upside of 273.13%. Given SCYNEXIS’s higher probable upside, research analysts plainly believe SCYNEXIS is more favorable than Scienture.

Profitability

This table compares SCYNEXIS and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Scienture	N/A	-56.28%	-44.76%

Risk & Volatility

SCYNEXIS has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Scienture has a beta of 3.32, suggesting that its stock price is 232% more volatile than the S&P 500.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.